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Time above the minimum inhibitory concentration of piperacillin/tazobactam as a 1 
predictor of outcome in Pseudomonas aeruginosa bacteraemia 2 
Abstract 3 
Pseudomonas aeruginosa bacteraemia is an infection associated with high mortality 4 
rate. Piperacillin + Tazobactam is a β-lactam β-lactamase inhibitor combination that 5 
is frequently used for the management of Pseudomonas aeruginosa . The 6 
pharmacokinetic-pharmacodynamic index associated with in-vitro maximal bacterial 7 
killing for Piperacillin + Tazobactam  is the percentage of time at which the free 8 
fraction concentration is above the minimum inhibitory concentration (%fT>MIC). 9 
However, the precise %fT>MIC target associated with improved clinical outcomes is 10 
unknown.  11 
The aim of this study was to investigate the correlation between survival of patients 12 
with Pseudomonas aeruginosa  bacteraemia and the threshold of Piperacillin + 13 
Tazobactam %fT>MIC. This retrospective study included all adult patients 14 
hospitalized over an 82 month period with Pseudomonas aeruginosa  bacteraemia, 15 
and treated with Piperacillin + Tazobactam . Patients with a polymicrobial infection 16 
or those who died within 72 hours of culture, were excluded. The %fT>MIC of 17 
Piperacillin + Tazobactam associated with in-hospital survival was derived using 18 
Classification and Regression Tree analysis. After screening 270 patients, 78 were 19 
eligible for inclusion in the study; 18% died during hospitalization. Classification and 20 
Regression Tree analysis  identified %fT>MIC >60.68% as associated with improved 21 
survival, and this remained statistically significant after controlling for clinical 22 
covariates (OR= 7.74, 95% CI 1.32-45.2). In conclusion, the findings recommend 23 
dosing of Piperacillin + Tazobactam with the aim of achieving a pharmacodynamic 24 





 Pseudomonas aeruginosa (PA) bacteraemia is a common hospital-acquired 28 
infection (1), associated with increased mortality, ranging between 18-61% (2).  29 
Early appropriate antimicrobial therapy is associated with improved survival (3–8). 30 
Piperacillin and the combination of piperacillin and tazobactam (TZP) are extensively 31 
used in the treatment of infectious diseases in critically ill patients; specifically, when 32 
PA is the causative pathogen (8). Protein binding for piperacillin ranges between 20-33 
30% and for tazobactam it is approximately 30% (9, 10). Various population 34 
pharmacokinetic studies have suggested that the main covariates influencing the 35 
volume of distribution and clearance of TZP were weight and creatinine clearance, 36 
respectively (11–16). The usual dose of TZP is 4.5g three times daily for most 37 
infections and may be increased to 4.5g four times daily in severe health-care 38 
acquired infections  (17), and in PA infections, as recommended by the European 39 
Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and 40 
Laboratory Standards Institute (CLSI). Dose adjustments for renal impairment vary 41 
widely between sources (9, 17, 18). There is no sufficient data regarding dosing 42 
regimens that will achieve pharmacokinetic and pharmacodynamic (PK-PD) targets 43 
that are correlated with improved clinical outcomes. 44 
Piperacillin, like other β-lactams, exhibits a time-dependent bactericidal activity. In-45 
vitro and animal studies suggest that the PK-PD parameter for β-lactams that is 46 
most predictive of microbiological efficacy, is the percentage of time between doses 47 
at which the free fraction concentration remains above the minimum inhibitory 48 
concentration (%fT>MIC) (19). For piperacillin, a PK-PD target of 50% fT>MIC is 49 
often cited based on studies on other penicillins (20), for example ticarcillin (21, 22). 50 
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There is only one study that reported a relationship between bacterial kill and 51 
%fT>MIC with significant thresholds of 27% for bacteriostasis and 75% for 52 
bactericidal activity (23).   53 
Very few studies have tried to correlate %fT>MIC with clinical outcomes. Among 54 
them is the DALI trial, a prospective multinational study that included 361 critically ill 55 
patients who were treated with a β-lactam (24). This study concluded that for all β-56 
lactams a %fT>MIC >50% is associated with better outcomes.  Other studies dealt 57 
specifically with Meropenem and neutropenic patients (25), and cephalosporins (26, 58 
27).  59 
Moreover, the need for a clinically driven %fT>MIC target is augmented by the fact 60 
that β-lactams display indirect antimicrobial properties. These properties cannot be 61 
identified by the standard in-vivo susceptibility testing and include synergy with 62 
cationic host defence peptides and action as immune-adjuvants (28). The use of an 63 
in-vitro derived PK-PD target for any antimicrobial without clinical validation is highly 64 
problematic (29). This observation is especially true in the case of β- lactams. 65 
The aim of this study was to investigate the correlation between the 66 
concentration/time profile of TZP and clinical outcomes in patients with PA 67 
bacteraemia. Additionally the study aimed to find if there is a threshold of %fT>MIC 68 
that is associated with improved survival at 30 days.  69 
Results 70 
A total of 270 patients with PA bacteraemia were screened for this retrospective 71 
study during January 2012- October 2018, and 78 fulfilled the inclusion criteria for 72 
the study. (Figure 1) 73 
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Baseline patients' characteristics are described in Table 1. Included patients had a 74 
mean (SD) age of 65 years (±17.95), 37.1% were female and mean (SD) modified 75 
APACHE II score on culture day was 11.5 (±5.46). Patients had a median (IQR) 76 
creatinine clearance of 53.5 mL/min ( 23.25-97), and 16 patients (20.5%) had an 77 
acute kidney injury (AKI). The most common source of bacteremia was respiratory 78 
(28.2%) and 7 (9%) patients were treated in the intensive care unit (ICU). Median 79 
MIC was 8 mcg/mL and was similar among patients who survived and patients who 80 
died.  81 
The primary outcome of in-hospital survival occurred in 64 (82%) of included 82 
patients.  Patients who survived had a lower APACHE II score, fewer cases of AKI, 83 
and were less frequently hospitalized in the ICU than patients who died (10.8 vs 84 
14.5, p=0.022, 14% vs 50%, p=0.003, 4.7% vs 28.6%, p=0.005, respectively).  85 
The estimated median volume of distribution of piperacillin was 23.19 L (IQR= 18.47-86 
30.19) and the estimated median elimination rate constant was 0.56 h-1 (IQR= 0.36-87 
0.86). The mean %fT>MIC calculated from the pharmacokinetic model and 88 
estimated parameters was 63% (IQR= 47-85). Table 2 presents median %fT>MIC 89 
by different creatinine clearance groups. Patients with creatinine clearance less than 90 
20mL/min had a higher median %fT>MIC  as compared to patients with creatinine 91 
clearance above 20mL/min (82% and 59%, respectively).  92 
Classification and Regression Tree analysis (CART) identified  a %fT>MIC threshold  93 
of  60.68%,  as associated with improved in-hospital survival, adjusting for creatinine 94 
clearance (Figure 2).  95 
The final logistic regression model included AKI, modified APACHE II score ≥ 14, 96 
and an interaction term between them as independent variables, in addition to the 97 
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CART derived %fT>MIC threshold.  fT>MIC > 60.68% was entered in the final model 98 
as a categorical variable. The adjusted odds ratio of achieving the threshold of 99 
fT>MIC > 60.68% was 7.74, 95% CI 1.32-45.2. (Table 3) Comparison between the 100 
final model and competing models is summarized in table 1 in the supplementary 101 
material.  102 
Goodness of fit and regression diagnostics of the final model are summarized in 103 
tables 2-4 in the supplementary material. Internal validation with bootstrap analysis 104 
is summarized in tables 5 and 6 in the supplementary material.  Moreover, other 105 
%fT>MIC thresholds were tested adjusting for the same covariates, as shown in 106 
Table 4. %fT>MIC> 40% and %fT>MIC> 50%, as well as %fT>MIC> 70% and 107 
%fT>MIC> 80% were not significant predictors of in-hospital survival. 108 
Eleven patients received concomitant treatment with other antimicrobial agents: 109 
Ciprofloxacin (n=9), Levofloxacin (n=1) and Gentamicin (n=1). In univariable analysis 110 
for 30 day survival the OR of concomitant treatment was 0.3 (p= 0.0984). In the 111 
multivariable logistic regression adding this variable did not increase the explanatory 112 




The key finding of this study is the fact that the CART derived threshold of 117 
%fT>MIC> 60.68% of TZP was found to be a significant predictor of in-hospital 118 
survival in patients with PA bacteremia, adjusting for covariates. Lower thresholds 119 
(%fT>MIC > 40% and %fT>MIC > 50%), as well as higher thresholds (%fT>MIC > 120 
70% and %fT>MIC > 80%) were not significant predictors of in-hospital survival. To 121 
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the best of our knowledge, this is the first study to report a %fT>MIC threshold of 122 
TZP that is associated with improved survival. 123 
The results of this study are consistent with other clinical studies concerning the 124 
effects of %fT>MIC of β-lactams on clinical outcomes. In the DALI study, achieving a 125 
%fT>MIC >50% and %fT>MIC >100% was associated with improved clinical 126 
outcomes (24). This cohort had a relatively lower mean modified APACHE II score 127 
compared to the DALI study (11.5 and 18, respectively). Interestingly, in the DALI 128 
study, the adjusted odds ratio of %fT>MIC >50% and %fT>MIC >100% for improved 129 
clinical outcome were similar among patients who did not receive renal replacement 130 
therapy (1.03 [95%CI 1.01-1.04] and 1.02 [95%CI 1.01-1.05], respectively). This 131 
latter finding is consistent with the threshold of %fT>MIC >60% reported in this 132 
study.  133 
Ariano et al studied the influence of %fT>MIC of meropenem in neutropenic patients 134 
with bacteraemia and found an average of 83% fT>MIC among 42 clinical 135 
responders compared with 59% fT>MIC for the 18 non-responders (p = 0.04), but in 136 
their study no adjustment for severity of illness was performed (25). Rhodes et al 137 
reported two % fT>MIC thresholds for Cefepime (68% and 74%) that were 138 
associated with improved survival (adjusted OR 7.12 [95% CI 1.9-26.7] and 6.48 139 
[95% CI 1.9-22.1], respectively) (27), similar to our results, although our patient 140 
population had a lower mean modified APACHE II score (11.5 and 14.6, 141 
respectively), and a lower median creatinine clearance (59.5 mL/min in patients who 142 
survived and 53.5 mL/min among patients who died in our study, compared to 74.9 143 
mL/min and 83 mL/min, respectively, in the study by Rhodes et al )(27).  144 
The EUCAST rational document for TZP states that a piperacillin %fT>MIC of 30-145 
35% is needed for stasis against PA, and a 40% fT>MIC is required for a 2 log drop 146 
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in viable organisms in animal models. This statement is based on limited data (30). 147 
Yet, a higher dose of 4.5g four times daily is recommended. This higher dose, 148 
according to EUCAST, renders all wild type PA susceptible to TZP and allows a 149 
clinical MIC breakpoint of 16mg/L. The former conclusion was based on a Monte-150 
Carlo simulation of varying dosing regimens. It did not consider special populations 151 
such as critically ill patients, who usually have higher piperacillin volume of 152 
distribution and patients with augmented renal clearance, whose piperacillin 153 
clearance is significantly increased. Indeed, Udy et al demonstrated that patients 154 
with augmented renal clearance had increased clearance of piperacillin. They 155 
concluded that when considering the MIC distribution of PA, the 4.5g four times daily 156 
regimen administered as a 30-minute infusion is not expected to achieve 50% 157 
fT>MIC in a significant portion of critically ill patients (31). The cohort in this study 158 
was too small to analyze the optimal dosing regimen.  159 
There are some limitations to this study. First, this was a retrospective, single-centre 160 
study with the limitations resulting from the study design. Still, results contribute to 161 
evidence in an area where there is limited literature available. Second, the small 162 
sample size may have affected the estimation of the adjusted odds ratio of %fT>MIC 163 
> 60% of TZP on in-hospital survival, as reflected by large confidence intervals in 164 
some of the results. Third, TZP concentrations were not measured in any patient 165 
and former studies have shown substantial variability in TZP concentrations in 166 
hospitalized patients (24). Nevertheless, piperacillin volume of distribution and 167 
elimination rate constant was estimated for each patient using a highly qualified 168 
population model. Moreover, across various population pharmacokinetics studies, 169 
weight and creatinine clearance were identified as the main covariates affecting 170 
piperacillin`s volume of distribution and clearance, respectively. Concentrations were 171 
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predicted for each patient controlling for weight and creatinine clearance. Therefore, 172 
concentration prediction and imputation represented the best available strategy to 173 
study the influence of %fT>MIC on in-hospital survival in our patient cohort.  174 
This study has several strengths. First, data was extracted and reviewed by two 175 
health care professionals reviewing all medical records. Second, exact dosing times 176 
were used to calculate %fT>MIC and symmetric dosing intervals were not assumed; 177 
an assumption that is mostly inaccurate in the hospital setting (31). Third, creatinine 178 
clearance was estimated using three different methods, to account for patients with 179 
unstable serum creatinine and patients whose weight was 30% higher than their 180 
ideal body weight. Fourth, the logistic regression model utilised purposeful variable 181 
selection as a model building strategy that includes testing for interactions between 182 
selected variables. Fifth, the final logistic model was tested for goodness of fit and 183 
rigorous regression diagnostics were performed and the final model was internally 184 
validated with bootstrap analysis. 185 
Additionally, the findings of the present study support dose individualization of TZP 186 
with the aim of achieving a threshold of 60% fT>MIC. In settings where therapeutic 187 
drug monitoring of TZP is available, concentration monitoring is recommended for 188 
critically ill patients with PA bacteraemia in order to achieve the pharmacodynamic 189 
target of 60% fT>MIC. 190 
 191 
In conclusion, we have found that achieving a 60% fT>MIC of TZP was associated 192 
with improved in-hospital survival in patients with PA bacteraemia. Until more data is 193 
available, it is prudent to recommend dosing TZP with the aim of achieving the 194 





This retrospective study was conducted at a secondary university affiliated hospital 198 
with 495 beds. Study methods were approved by the ethics committees at Hillel 199 
Yaffe Medical Center, Hadera, Israel, and Robert Gordon University, Aberdeen, 200 
Scotland. Patients above 18 years old, with a positive blood culture for PA and who 201 
were hospitalized in our medical center between January 2012 and October 2018, 202 
were reviewed for inclusion. Patients not treated with TZP, or for whom treatment 203 
was delayed >96 hours of indexed blood culture or having polymicrobial blood 204 
culture or cases where the MIC of TZP was not reported, were excluded. Moreover, 205 
patients who had died in less than 72 hours of obtaining a blood culture were 206 
excluded. If a patient had two episodes of PA positive blood cultures in less than 207 
three months, only the first episode was included. 208 
Information was extracted from paper-based and electronic patient records. PA 209 
blood cultures were extracted from the microbiology laboratory data base, as well as 210 
MICs for TZP. Extracted data included: age, gender, comorbidities, modified 211 
APACHE II score (32, 33), Glasgow coma scale, absolute neutrophil count, weight, 212 
serum creatinine, TZP dose and dosing interval. In cases of patients with stable 213 
serum creatinine (defined as a difference less than 0.3mg/dl between two 214 
consecutive serum creatinine levels), creatinine clearance was estimated using the 215 
Cockroft and Gault equation for patients whose actual body weight was no more 216 
than 30% greater than their ideal body weight, and otherwise the Salazar-Corcoran 217 
equation was used. In patients with unstable serum creatinine the Jelliffe equation 218 
was used.  219 
Pharmacokinetic analysis: 220 
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To estimate %fT>MIC of piperacillin, we utilized a population pharmacokinetics 1- 221 
compartment model published by Chen et al. (15). This model was selected because 222 
it best fitted the population in our study, reported inter-subject variability, was 223 
qualified by visual predictive checks and was validated using non-parametric 224 
bootstrap analysis. Using NONMEM 7.4 the volume of distribution and clearance 225 
were estimated for each patient. Subsequently, for each patient, the free fraction 226 
piperacillin concentration was generated every 15 minutes for the first 48 hours of 227 
TZP treatment, assuming a mean protein binding of 25%. The cumulative time 228 
above MIC was calculated and divided by 48 giving the estimated %fT>MIC of 229 
piperacillin. MIC was determined using Vitek 2 (Vitek 2®, bioMérieux). 230 
The primary outcome was in-hospital survival.  231 
 Statistical analysis 232 
Statistical analysis was performed by SPSS 25 and R. The %fT>MIC threshold 233 
associated with improved survival was derived by using the classification and 234 
regression tree (CART) analysis function in SPSS 25, using %fT>MIC and creatinine 235 
clearance as continuous independent variables.  236 
To test the influence of the CART derived %fT>MIC threshold on in-hospital survival 237 
adjusting for significant covariates, a logistic regression model was utilized. Variable 238 
selection was performed using purposeful variable selection (34).In brief, candidate 239 
variables at a univariate level of significance of P<0.25 were assessed as possible 240 
predictors of in-hospital survival. The importance of each variable was tested using 241 
the likelihood ratio test with one degree of freedom. Variables were retained in the 242 
model if there deletion resulted in a change of > 3.84 in the likelihood ratio. (47) 243 
Moreover, the presence of interactions among retained variables was explored and 244 
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significant interactions were added into the final model (34). Goodness of fit was 245 
assessed using the Hosmer and Lemeshow test in SPSS 25, and regression 246 
diagnostics were performed using the "car" package in R (35). (See supplementary 247 
material). Internal validation of the final model was performed with bootstrap analysis 248 
using the "boot" package in R. (20,000 replications, confidence intervals were 249 
calculated using the percentile method; See supplementary material ) 250 
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Figure 1- Study flow chart 371 
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Study population, n=78 
Survived = 64 
Died = 14 
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Table 1: Baseline characteristics of 78 patients with PA bacteremia  389 
 Total cohort Survived in-
hospital 
Died  P-value 
Total number of 
patients (%) 
78 64 (82%) 14 (18%)  
Age, years, mean 
(SD) 
65 (17.95) 65 (18.27) 68 (16.82) 0.568 
Female n, (%) 29(37.1) 24 (37.5) 5 (35.7) 0.900 




74 (84.25, 62.75) 71 (74, 61.75) 0.108 
Modified APACHE 
II score on culture 
day, mean (SD) 
11.5 (5.46) 10.8 (5.61) 14.5 (3.48) 0.022 




































































































59.5 (98.5, 26.95) 26.5 (78.25, 
13.525) 
0.214 
AKI, n (%) 16 (20.5) 9 (14) 7 (50) 0.003 
Solid tumours, n 
(%) 
Hematological 


























1 (2,0) 1 (2,0) 1 (2.75,1) 0.603 
Treated in ICU, 
days, mean (SD) 
7 (9) 3 (4.7) 4 (28.6) 0.005 
IQR, interquartile range; IHD, ischemic heart disease; CKD, chronic kidney disease; 
COPD, chronic obstructive pulmonary disease; AKI, acute kidney injury; ICU, 
intensive care unit.  
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Table 2: %fT>MIC by different creatinine clearance groups 392 
Creatinine clearance 
mL/min  
%fT>MIC, median %fT>MIC, IQR 
0-20 (n=19) 82 69-89 
21-40 (n=19) 65 45-85 
41-60 (n=5) 47 43-90 
61-80 (n=5) 69 55-99 
81-100 (n=11) 53 40-70 
101-120 (n=6) 54 50-60 
>120 (n=13) 56 35-75 
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Table 3: Logistic regression model of in-hospital survival 395 
 Adjusted OR for in-
hospital survival 
P-value 95% CI 
%fT>MIC > 60% 7.74 0.023 1.32-45.2 
AKI 0.14 0.003 0.001-0.234 
Modified APACHE 
II ≥ 14 
0.113 0.018 0.019-0.685 
AKI * Modified 
APACHE II ≥ 14 
20.65 0.05 1.99-420.8 
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Table 4: Different %fT>MIC thresholds effect on in-hospital survival 398 
 Adjusted OR for in-
hospital survival 
P-value 95% CI 
 %fT>MIC > 40% 3.70 0.151 0.62-22 
%fT>MIC > 50% 3.76 0.100 0.77-18.18 
%fT>MIC > 60% 7.74 0.023 1.32-45.2 
%fT>MIC > 70% 2.55 0.199 0.61-10.65 
%fT>MIC > 80% 2.25 0.280 0.52-9.82 
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